Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis shows ribociclib reduces costs compared to palbociclib in postmenopausal women with advanced breast cancer.
Ribociclib plus letrozole is cost-saving and cost-effective compared to palbociclib plus letrozole for the first-line treatment of postmenopausal women with HR+/HER2- advanced BC in Chile.
No takes yet. Share an insight, caveat, or question.
Balmaceda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: